Previous 10 | Next 10 |
Eiger BioPharmaceuticals Appoints Commercial Expert and Industry Veteran Kim Sablich to its Board of Directors PR Newswire PALO ALTO, Calif. , April 22, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceuti...
Goodrx (NASDAQ: GDRX) recently released its list of the 10 most expensive drugs on the market. Novartis ' (NYSE: NVS) gene therapy Zolgensma remains at the top, but newcomers Eiger Pharmaceuticals (NASDAQ: EIGR) and Y-mAbs Therapeutics (NASDAQ: YMAB) took sec...
Eiger BioPharmaceuticals' first approved therapy, Zokinvy (lonafarnib), for the treatment of ultra-rare Hutchinson-Gilford progeria syndrome, launched in January 2021. Lonafarnib – boosted by ritonavir – as well as the company’s clinical asset lambda, have demonst...
Eiger BioPharmaceuticals (EIGR): Q4 EPS of -$0.58 may not be comparable to consensus of $0.38.Cash, cash equivalents, and short-term investments as of December 31, 2020 totaled $128.8 million compared to $95.0 million on December 31, 2019. In addition, the Company received net proceeds ...
Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update - Phase 3 HDV D-LIVR (Lonafarnib) to Complete Enrollment in 2021 - Phase 3 HDV LIMT-2 (Lambda) to Initiate in 2021 - Strong Cash Position with $176 Million P...
Eiger Announces Publication of Phase 2 PREVENT Study Results of Avexitide in Post-Bariatric Hypoglycemia in Journal of Clinical Endocrinology & Metabolism Eiger Announces Publication of Phase 2 PREVENT Study Results of Avexitide in Post-Bariatric Hypoglycemia in Journal of C...
EIGR just got approval for progeria. The stock didn't improve much probably because progeria is a minuscule market. Its next indication is Hepatitis D, and that is not a small market. For further details see: Eiger Pharma: Next Up Is HDV
Eiger Announces ILIAD Study Results of Peginterferon Lambda in COVID-19 Published in Lancet Respiratory Medicine 2021 - Lambda has potential to improve clinical outcomes and curb community spread - Fewer emergency room visits with Lambda treatment compared to placebo PR ...
Eiger BioPharmaceuticals Announces U.S. Commercial Availability of Zokinvy™ (lonafarnib), the First and Only Treatment Approved for Progeria and Processing-Deficient Progeroid Laminopathies - The Eiger OneCare™ Program Provides Ongoing Patient Support Services ...
Eiger BioPharmaceuticals ([[EIGR]] -5.6%) expects EMA approval for its Hutchinson-Gilford progeria syndrome treatment Zokinvy, and plans to start its Phase 3 HDV LIMT-2 ((Lambda)) trial, both in the second half of this year.Lambda is a well-tolerated interferon in development for HD...
News, Short Squeeze, Breakout and More Instantly...
Eiger BioPharmaceuticals Inc. Company Name:
EIGR Stock Symbol:
NASDAQ Market:
Eiger BioPharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Nikola Corporation (NKLA) rose 6.5% to $0.95 on volume of 182,734,103 shares WiSA Technologies Inc. (WISA) fell 3.3% to $0.0235 on volume of 160,634,740 shares PROSHARES TRUST (SQQQ) rose 4.7% to $11.12 on volume of 151,373,755 shares...
A look at the top 10 most actives in the United States Sunshine Biopharma Inc. (SBFM) rose 76.0% to $0.1065 on volume of 290,483,542 shares CXApp Inc. (CXAI) rose 151.0% to $6.15 on volume of 236,739,031 shares Nikola Corporation (NKLA) fell 1.0% to $1.03 on volume of 123,276,764 shares ...
Announces “Stalking Horse” Agreement for the Sale of Zokinvy ® (lonafarnib) Patient Access to Zokinvy ® to Continue Uninterrupted PALO ALTO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) today ...